文献速递核素与放射性配体治疗肿瘤 PET/CT

镥-177 DOTATATE 治疗后 1/2 级神经内分泌肿瘤新疗效评估标准 RECIN 的构建:2 期 LuCAP 试验事后分析

Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-26

本研究为 2 期 LuCAP 试验的事后分析,纳入 72 例生长抑素受体阳性的晚期 1/2 级胃肠胰神经内分泌肿瘤患者,接受[177Lu]Lu-DOTATATE±卡培他滨治疗,以连续[68Ga]Ga-DOTANOC-PET/CECT评估疗效。新提出的 RECIN-PR 定义为最高五个最热病灶的 SULpeak 总和下降≥25%或 RECIST-PR 且无影像学进展征象;40/72(56%)达到 RECIN-PR,其中 42 例 RECIST 稳定患者中 17 例(40%)达到 RECIN-PR。RECIN-PR 与更好的无进展生存相关(HR 0.33,95%CI 0.15-0.76;C-index 0.67),预测能力优于 RECIST-PR(HR 0.52,95%CI 0.21-1.29;C-index 0.60)。

要点

  • RECIN-PR 定义为最高五个最热病灶 SULpeak 总和下降≥25%,或 RECIST-PR 且无影像学进展征象
  • 72 例中 40 例(56%)达到 RECIN-PR,RECIST 稳定患者中 40%(17/42)达到 RECIN-PR
  • RECIN-PR 与更好 PFS 相关(HR 0.33,95%CI 0.15-0.76),预测能力优于 RECIST-PR

核心结论

  • 在[177Lu]Lu-DOTATATE 治疗的晚期 1/2 级神经内分泌肿瘤中,基于[68Ga]Ga-SSA-PET/CT 的新 RECIN 框架在惰性疾病早期疗效检测和预测能力方面优于传统影像学疗效评估。

研究设计与样本

  • 本研究为 2 期 LuCAP 试验的事后分析,纳入 72 例生长抑素受体阳性的晚期 1/2 级胃肠胰神经内分泌肿瘤患者,接受[177Lu]Lu-DOTATATE±卡培他滨治疗。
  • 采用连续[68Ga]Ga-DOTANOC-PET/CECT 评估肿瘤疗效,按 RECIST 1.1 评估最多五个靶病灶的影像学疗效,并评估最多五个最热病灶的 SULpeak 总和用于分子疗效。
  • 采用风险比(HR)及其 95%置信区间(95%CI)以及 Harrell C 指数评估与无进展生存(PFS)的关联。

主要发现

  • 72 例患者中 23/72(32%)达到 RECIST 部分缓解(PR)。
  • 40/72(56%)患者达到 RECIN-PR;42 例 RECIST 稳定疾病患者中 17 例(40%)达到 RECIN-PR。
  • RECIN-PR 与显著更好的 PFS 相关(HR 0.33,95%CI 0.15-0.76;C-index 0.67)。
  • RECIST-PR 与 PFS 的关联为 HR 0.52(95%CI 0.21-1.29;C-index 0.60),未达统计学显著。
  • RECIN-PR 的预测能力优于 RECIST-PR(C-index 0.67 对 0.60)。

关键数值与推荐

  • RECIN-PR 定义为最高五个最热病灶的 SULpeak 总和下降≥25%,或传统 RECIST-PR 且无影像学进展征象。
  • RECIST-PR 按 RECIST 1.1 评估最多五个靶病灶。
  • 分子疗效评估采用最多五个最热病灶的 SULpeak 总和。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Treatment response assessment in grade 1/2 neuroendocrine tumors (NETs) has been a key challenge due to their indolent nature. Here, we propose the novel response evaluation criteria with [68Ga]Ga-somatostatin analogue (SSA)-PET/CT in grade 1/2 NETs (RECIN) following [177Lu]Lu-DOTATATE therapy and evaluate its survival impact vis-à-vis conventional radiographic response assessment. METHODS: This was a post-hoc analysis of the phase 2 LuCAP trial, wherein somatostatin receptor-positive, advanced grade 1/2 gastroenteropancreatic NET patients were treated with [177Lu]Lu-DOTATATE ± capecitabine. Tumor response assessment was done with serial [68Ga]Ga-DOTANOC-PET/CECT. Up to five target lesions were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for radiographic response. Summed SULpeak of maximum five hottest lesions were evaluated for molecular response. Associations with progression-free survival (PFS) were evaluated using hazard ratios (HRs) and their 95% confidence intervals (95%CIs) along with Harrell's C-index. RESULTS: Seventy-two patients were included with 23/72 (32%) patients achieving RECIST-partial response (PR). The novel RECIN-PR was defined as ≥ 25% decrease in summed SULpeak or conventional RECIST-PR with no signs of radiographic progression. Based on this, 40/72 (56%) patients achieved RECIN-PR. In particular, of the 42 patients with RECIST-stable disease, 17 (40%) had RECIN-PR. RECIN-PR was associated with significantly better PFS (HR: 0.33, 95%CI: 0.15-0.76; C-index: 0.67) and had better predictive ability compared to RECIST-PR (HR: 0.52, 95%CI: 0.21-1.29; C-index: 0.60). CONCLUSION: In advanced grade 1/2 NETs treated with [177Lu]Lu-DOTATATE, [68Ga]Ga-SSA-PET/CT-based novel RECIN framework proved superior to conventional radiographic response assessment in terms of early response detection in indolent disease and better predictive ability. CLINICAL TRIAL REGISTRATION: Clinical Trials Registry-India, CTRI/2020/01/022636.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Satapathy S, Aggarwal P, Sood A, et al. Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial. Eur J Nucl Med Mol Imaging. 2025. PMID: 40414996. doi:10.1007/s00259-025-07351-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。